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1Is cannabis a gateway to hard drugs?
1 Introduction
Cannabis is sometimes said to be a gateway drug that increases the user’s probability of 
taking up harder drugs like amphetamine, cocaine or heroin. The empirical basis for the 
hypothesis is the common finding that most hard drug users have started with less 
dangerous drugs first and that there seems to be a “staircase” from alcohol and solvents 
via cannabis and tablets to amphetamine, cocaine and heroin (see e.g. Kandel 1975). 
Although controversial, the hypothesis has had considerable influence on drug policy 
and legislation in many countries and has been a powerful argument in debates about 
legalization or decriminalization of cannabis. For instance, when asked about marijuana
laws at a meeting in 2007, US Senator John McCain answered that "I believe that 
marijuana is a gateway drug. That is my view and that's the view of the federal drug 
czar and other experts, although that is also a debatable question”1  In contrast to this, a 
former cabinet minister in the UK, Peter Lilley, has argued that the gateway argument 
“is the reverse of the truth. Making the supply and possession of cannabis a criminal 
offence drives people through the gates of the law into the illegal world in which they 
must acquire their supplies from people who may also push heroin, cocaine and other 
hard drugs.”2
                                                
1
The comment is publicly available on a video on the Internet 
(http://www.youtube.com/watch?v=JzkREVOVYsw) and is from meeting at Milton, New Hampshire on 
August 11, 2007.
2  The comment was made in a debate in the House of Commons and is recorded in the Commons 
Hansard Debates text for Friday 9 Nov 2001, Volume No. 374, Part No. 048: Column 519.
2Liberalizing cannabis laws may increase the number of users as it will lower the 
opportunity cost of using the drug and probably increase the physical and cultural 
availability (see e.g. Williams (2004) for a review of cannabis participation studies). 
Whether such liberalization subsequently will lead to an increase in the number of hard 
drug users depends, among other things, on whether there is a gateway effect or not. 
The purpose of this paper is to test whether there is evidence of such a causal link 
between the uptake of cannabis and hard drugs.
There are different pathways that might be the basis for a causal gateway effect 
in drug use. For instance Pudney (2003, p. 183c) lists three: 
"One is the nature of consumer preferences: the consumption of soft drugs may 
create a psychological or physiological need for further, stronger experiences of 
the same type. Another is through social interaction: the act of obtaining and using 
soft drugs may bring the user into contact with hard-drug users or suppliers whom 
they would not otherwise have met. A third is through information and credibility:
experience of the use of soft drugs with no obvious ill effects may appear to 
contradict and undermine the strong negative publicity directed against the use of 
illicit drugs in general, so that advice against hard drugs becomes less persuasive."  
In addition there may be an adjustment cost effect: for some individuals consuming any 
illicit drug may cross a psychological threshold that makes it less costly to proceed into 
another stage of drug use. 
Testing for a gateway effect with retrospective survey data poses a statistical 
challenge as it involves dealing with selection bias due to unobserved individual 
heterogeneity. The apparent causal relationship in the observed association may be 
spurious since unobserved factors may influence both the probability of cannabis use 
and the use of other drugs. For instance, a traumatic childhood may be causally 
important for both cannabis and later heroin use. If this factor is unobserved, the effect 
of childhood trauma will be picked up by the variable for cannabis use.  It would be 
3misleading to conclude that cannabis is a gateway drug since it picks up the effects of an 
omitted third variable.
Two recent tests of the hypothesis report that the gateway effect of cannabis is 
greatly reduced after taking unobserved heterogeneity into account, even to the point of 
not being statistically significant (Beenstock and Rahav 2002; Pudney 2003). Other 
recent studies claim, on the other hand, that although the gateway effect is reduced 
when unobserved heterogeneity is taken account of, there is still a significant 
association (van Ours 2003; Fergusson et al. 2006; Bretteville-Jensen et al. 2008). 
Hence, the core question of whether the observed sequential pattern of drug initiation is 
due to correlation or causality remains unresolved. 
This paper builds on this literature and makes new methodological and empirical 
contributions. The paper develops a new approach for testing the hypothesis using a 
latent class bivariate hazard model in which both the intercept and all slope coefficients 
are estimated separately for each latent class. The main difference between this 
approach and the ones employed by van Ours (2003) and Pudney (2003), is that the 
individual heterogeneity is allowed to affect the marginal effects of all the variables and 
not only the random intercept. In this sense, it imposes fewer restrictions on the model 
that is used to test the gateway hypothesis. 
Previous studies have attempted to identify the gateway effect by comparing 
patterns of initiation of hard drugs between cannabis users and non-users, effectively 
using non-users as the control group. This approach is problematic when there is 
unobserved heterogeneity that makes users and non-users systematically different from 
each other: comparing treatment and control groups may fail to compare like-with-like. 
In contrast, our strategy is to restrict the analysis to those who have used cannabis at 
4some point in their lives and to exploit variation in the timing of cannabis and hard drug 
initiation to identify the gateway effect. This avoids the problem of having a non-
comparable control group. There may still be systematic unobservable heterogeneity 
within the group of cannabis users, but this is dealt with by using a bivariate hazard 
specification with shared frailty (see Abbring and van den Berg, 2003).
The empirical results benefit from a unique set of data on drug prices collected 
through face-to-face interviews with people visiting the needle exchange service in the 
city of Oslo, Norway. Data on drug prices are rare, especially price information 
provided directly by users. Changes in the relative prices of drugs may affect the choice 
of which drug to use first (if at all) and for this reason having reliable information about 
prices is important. Previous contributions have either adopted approaches in which 
price variables were ignored or have tried to create proxies for prices. 
Our findings demonstrate, first of all, that there is a gateway effect and the 
hazard of taking up hard drugs increases substantially after the initiation of cannabis. 
Results from the univariate hazard model suggest that the hazard of starting to use hard 
drugs more than doubles (2.6) after controlling for the influence of other observable 
factors. Secondly, the results demonstrate the importance of taking unobserved 
heterogeneity into account. The effect of recent cannabis use differs considerably 
between two groups of users when a latent class analysis is employed. For a small group 
that we label “troubled youths”, we find that recent use of cannabis doubles the hazard 
of starting to use hard drugs. For the second group – labeled “most youths” - recent
cannabis use makes less difference to the hazard of using hard drugs and the coefficient
is statistically significant only at the 10% level. Although the relative hazard rate 
increases by 34 per cent, one should keep in mind that the marginal hazard for "most 
5youths" is very low (0.00023). Thus, the analysis indicates that the overall gateway 
effect is created by a large effect in a small group and a weaker effect for most people. 
2  Identifying the gateway effect
To identify a possible causal effect of cannabis on subsequent use of hard drugs one 
needs to account for self-selection into the group of cannabis users and into the group of 
hard drug users. Ideally, to single out the effect of cannabis use, one would like to know 
the counterfactual outcome for cannabis users: what the probability of hard drug use 
would have been if they had not started to use cannabis in the first place. In practice this
counterfactual cannot be observed and, in the absence of randomized experiments, 
attention must focus on alternative estimation strategies for handling the potential 
endogeneity of the gateway variable. 
One response to the problem of spurious correlation between the use of cannabis 
and hard drugs is to adopt a selection on observables strategy and include as many as 
possible of the potential confounders in the analysis as control variables. Yamaguchi & 
Kandel (1984) and Ferguson & Horwood (2000) are two studies that have included a 
wide range of variables that are assumed to influence drug use and deviant behavior. A
problem with this approach is that many variables affecting drug use are simply 
unavailable or are very difficult to measure.  For instance, in addition to childhood 
traumas, time preferences are sometimes argued to be an important causal factor in the 
decision to use illegal substances (Ainslie 1992). Although it is possible to measure 
(indicators of) time preference, this is seldom done in large surveys of drug use in the 
6population. Similarly, studies of twins suggest that genetic factors are important in 
determining an individual’s use of illegal drugs (Lyons et al. 1997), but this is, for all 
practical purposes, an unobserved variable for researchers who use general 
questionnaire-based surveys. In short, there are good reasons to expect that 
unobservable factors like emotional experiences, time preferences and genetics are 
important in the decision to use drugs and therefore it is necessary to take these 
unobservables into account when testing the gateway hypothesis that cannabis is a 
stepping stone to harder drugs.
One well-known approach is the instrumental variable (IV) technique. For 
instance, Pacula (1998) uses past prices of alcohol as instruments for previous 
consumption of the drug and estimates a gateway effect of alcohol on current use of 
marijuana. Other examples include DeSimone (1998), who uses two measures of state-
level penalties for marijuana possession and two alcohol related variables (beer tax and 
parent’s alcohol problems) as instrumental variables for predicting marijuana 
consumption and Beenstock and Rahav (2002), who apply variants of the IV approach 
to sequences of events using prices by birth cohorts as instruments. The main problem 
with the IV approach in general is finding valid instruments. From an economic 
perspective, prices can provide relevant instruments and alcohol and cigarette prices 
have been used frequently. These prices vary over time and between countries and 
states, but they cannot reflect contemporaneous individual differences in behavior
within the same area. This does not imply that the instrumental variable approach 
should be rejected, but it seems worthwhile to explore alternative approaches. Our 
access to unique data on drug prices is used as part of our identification strategy but we 
7also adopt a method that does not necessarily rely on exclusion restrictions and hence 
the need for instruments.
Depending on the types of data at hand and assumptions one is willing to 
impose, there are various ways to take account of unobserved factors. It is frequently 
assumed that unobserved variables are stable over time, specific to the individual and 
influence a range of behaviors. When analyzing retrospective survey data using duration 
models, one needs to create time-to-event data by taking advantage of questions that 
relate to events that have occurred at some earlier point in time. The structuring of the 
data as a panel is based on an underlying approach in which one uses bivariate or 
multivariate hazard models. Analysing two or more behaviors simultaneously allows the 
unobserved heterogeneity to be captured. Employing models of this kind usually 
requires exclusion restrictions (see e.g., Heckman and Honorè 1989) but an important 
paper by Abbring and van den Berg (2003) shows that sample variation in the timing of 
treatments and outcomes provides identifying information in hazard models without the 
need for such exclusion restrictions. Heckman and Navarro (2007) extend Abbring and 
van den Berg’s identification results in the context of dynamic discrete choice models 
for treatment effects. 
The intuition of this approach is that particular individuals may have unobserved 
characteristics (“fraility”) that make them more prone to both soft and hard drug use. 
This creates a potential selection bias in the sense that their hazard of initiating both soft 
and hard drugs will be higher, but without any direct gateway effect. However this 
frailty is modeled as time invariant heterogeneity using a shared frailty specification. 
Conditional on frailty, the treatment effect of interest (in our case the gateway effect) is 
identified by assuming that the actual timing of the treatment (initiation of cannabis use) 
8is random and is unaffected by the anticipation of the subsequent outcome (initiation of 
hard drugs). Under these assumptions the model is identified without exclusion 
restrictions. Here, as the assumptions may not be satisfied we also use exclusion 
restrictions, on drug prices, to strengthen identification. 
Both van Ours (2003) and Pudney (2003) employ retrospective survey data and 
refer to Abbring and van den Berg’s (2003) result as a source of identification in their 
hazard model specifications. van Ours (2003) analyses the use of cannabis and cocaine 
by employing a finite mixture approach to model the unobserved heterogeneity. Pudney 
(2003) takes a broader approach and analyses six categories of deviant behavior
simultaneously, including minor offending and serious crime in addition to solvent 
abuse, soft drug use, social drug use and hard drug use. He employs a discrete time 
hazard model and a parametric specification of the unobserved heterogeneity which is 
estimated using maximum simulated likelihood estimation. 
Given the nature of the information on drug use available in the Oslo survey data 
and the unique set of price data for illicit drugs at hand we too have chosen a hazard 
model approach. This means that identification of the causal gateway effect could be 
based solely on the timing of events, as demonstrated by Abbring and van den Berg. 
Compared to Pudney (2003) and van Ours (2003) we impose fewer restrictions on the 
model by allowing the unobserved variables to influence all the parameters of the 
model, not just the intercepts.  Identification is reinforced by using the price data as 
instruments.
Our focus is on testing whether cannabis is a gateway drug and because of the 
overlap in use and the nature of the drugs, we have chosen to merge use of 
amphetamine, cocaine and heroin into one cluster for hard drugs; we test whether recent
9cannabis use increases the probability of starting to consume a hard drug irrespective of 
which type of hard drug that might be. 
2.1 The model
Our starting point is a bivariate mixed proportional hazard model with shared frailty of 
the type discussed by Abbring and van den Berg (2003) in their approach to the 
identification of treatment effects with duration data. In our application the treatment is 
use of the gateway drug and the outcome of interest is initiation of hard drug use.  The 
first equation defines the hazard for initiation of cannabis use at a certain age, while the 
second equation estimates the hazard for initiation of hard drug use:
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ith is the hazard of individual (i) starting to use drug j (1=cannabis, 2=hard drugs) at age 
t, given the values of the covariates (x) and the shared frailty associated with an 
individual that affects both cannabis and hard drug use (unobservables u1 and u2 are 
correlated). λ1(.) and λ2(.) are the baseline hazards for cannabis and hard drug use. The 
function δ() captures the treatment effect, which depends on elapsed time (t), treatment 
time (s) and potentially on (t-s) the time between treatment and outcome. This 
formulation also allows for interactions with the covariates (x). This emphasis on the 
use of the timing of events to identify the treatment effects is exemplified by van Ours’ 
10
(2003) use of the concept of an “incubation period” to identify the gateway effect. He 
defines an indicator variable for whether use of cannabis had been initiated within a 
given number of years (the incubation period). We adopt a similar approach, using four 
years as the incubation period in our baseline model. 
The observed covariates (x) used in this paper can be categorized in three 
groups. First, to isolate the effect of cannabis, we control for time-dependent covariates 
(the price of cannabis, amphetamine, cocaine and heroin). Second, given the correlation 
between gender, childhood problems and drug use, we have included gender and self-
reported measures of serious childhood problems with parents, friends, police and 
school. Third, duration dependence is modelled using a cubic function of time (t). An 
alternative approach would be to use time dummies in a piecewise linear specification.
But, in the interest of making our results more directly comparable to Pudney (2003), 
we chose to follow his specification and use a smooth function for duration dependence.
Our sample consists of individuals all of whom are initially at risk of starting 
both cannabis and hard drugs and these individuals are then followed over time and we 
adopt a discrete-time hazard specification (see e.g., Lancaster 1990; Jenkins 1995). To 
estimate the hazard models we reorganize the data so that each individual (1,…, n) is 
associated with multiple observations – one at each point in time from the initial period 
until either the individual starts to use the drug or the time of the survey interview if 
they are a right censored observation (ti=1…tij). A new binary variable yit is created that 
equals 1 for the period at which drug use begins and 0 otherwise. For those individuals 
who do not start within the survey period yit always equals 0. For those who start, yit
only equals 1 in the final period and subsequently the individual is dropped from the 
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sample for all remaining periods. Using this reorganization of the data, the log-
likelihood for a univariate discrete-time hazard function can be written as:
1 1 1 1
log log[ ] (1 ) log[1 ]
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This log-likelihood takes the form of a standard binary choice model applied to the 
expanded dataset. Common choices of functional form for hit are the complementary 
log-log model, which is the discrete-time equivalent of a continuous-time proportional 
hazard specification, and the logit model, which gives a non-proportional hazard 
specification. 
This discrete-time specification can now be extended to the bivariate model for 
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where cj is a dummy indicating a non-censored case. For each hazard function, the 
product runs from t=1 to t=-1 for uncensored observations and t=1 to t= for censored. 
An observation is censored if substance j hasn’t been initiated by the end of the survey. 
The presence of unobservable heterogeneity (u) means that the two hazard functions 
must be estimated jointly and Eu{} denotes the expectation over the joint distribution of 
unobserved heterogeneity. Pudney (2003) adopts a parametric approach by assuming 
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that the u’s are jointly normally distributed and using maximum simulated likelihood 
estimation to deal with the numerical integration. van Ours (2003) adopts a 
semiparametric approach using a bivariate finite density estimator for u.
2.2 Latent class specification
In contrast to earlier studies, we adopt a latent class approach to deal with the presence 
of unobserved heterogeneity in the hazard functions. This approach has several 
advantages over previously applied methods for dealing with unobserved heterogeneity 
in models of the gateway effect. One advantage is that we can relax the parametric 
assumptions that are necessary in other approaches that rely on Gauss-hermite 
quadrature or maximum simulated likelihood estimation. We do not make assumptions 
about the parametric distribution of the unobserved heterogeneity. Another advantage is 
that the approach imposes fewer restrictions on the parameters of the model. For 
instance, in Pudney (2003) and van Ours (2003), only the constant term in the 
regression is assumed to differ depending on whether or nor the person has a high or 
low value on the unobserved characteristic. This is restrictive because there is no a 
priori reason to assume that the unobserved heterogeneity does not affect the marginal 
effects of the other variables. A person with adverse childhood experiences, for 
instance, may react differently to changes in prices than a person with a normal 
childhood. Hence, this more general approach allows all coefficients to vary. 
The latent class model assumes that each individual is drawn from one of K 
possible sub-groups or latent classes that exist in the population where k indicates the 
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share of the population that belongs to the group k.3 The parameters of the hazard 
function for each drug may be different depending on which group the individual 
belongs to. 
Given that the individual belongs to one of the two (or more) groups, and since 
we do not know which, we may use k  to denote the probability that individual i is a 
member of group k. The probability of an observed pattern for drug use is then the sum 
of the probability of observing the pattern conditional on group membership, weighted 
by the respective probabilities of being in each group. In this case the log-likelihood 
function for the whole sample can be written as:
2
1 1 1 1
1
log 1 log
















   

                       
   
   

This approach to capturing unobserved heterogeneity helps us solve the problem of
maximizing the likelihood function because it reframes the maximization problem in a 
way that allows us to use the EM algorithm (see for example, Ng et al. 2002).4 This is 
                                                
3 Previous results indicate that relatively few classes are needed (see for example Deb and  
Trivedi 1997)
4 The expectation (E) step uses Bayes’ rule for posterior probabilities to give an updated and 
improved estimate of the probability that an individual is a member of each latent class and 
these estimates can be substituted for the unknowns in the likelihood function. When we have 
estimates for the unknown individual heterogeneity (interpreted as probabilities of being a 
member of a group) it is possible to use weighted estimation of the binary choice models to 
estimate the coefficients of the hazard functions using that particular set of probabilities of 
group membership (this is the maximization (M) step). These coefficients give rise to a new set 
of estimates of the contributions to the likelihood which, in turn, can be used to improve the 
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possible since the unobserved heterogeneity is integrated out of the likelihood, in this 
case by factoring the sum over latent classes. The probabilities of class membership are 
treated as parameters to be estimated. 
3 The data
We combine two different data sources. The first dataset was collected through postal 
questionnaires sent to a representative sample of 21-26 year olds living in Oslo in 2002. 
It provides information on the development of drug use initiation in a general 
population of youths.  The data do not, however, contain any price information on illicit 
drugs so a second data source is required. Since 1993 the Norwegian Institute for 
Alcohol and Drug Research (SIRUS) has on a regular basis conducted face-to-face 
interviews with drug addicts visiting the needle exchange service in Oslo and prices for 
various types and quantities of drugs have been recorded
3.1 Data for drug use
The response rate for the postal questionnaires was roughly 50 percent, with more 
women than men answering the questions (see Table 1). A reminder was sent and a total 
of 1,984 questionnaires were registered. The respondents reported their experience with 
licit and illicit drugs in addition to information on age, gender and possible childhood 
                                                                                                                                              
estimates of class membership, and so on, until the likelihood converges. The algorithm is 
implemented in a Stata v.9 program that is available from the authors on request.
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problems with parents, friends, school and police. More than 40 per cent of the sample 
reported to have tried cannabis at least once in their life time. As mentioned, in order to 
reduce the problem of unobserved heterogeneity and compare like-with-like we have 
confined our analyses to these cannabis users only. For comparison, however, Table 1 
displays descriptive statistics for the cannabis users as well as for the sample as a whole.
(Table 1 about here)
There was no age difference between the full sample and the smaller group of cannabis 
users, the average age was 24 years in both. The proportion of males, however, was 
higher among the cannabis users (44 per cent versus 38 per cent) and a larger fraction of 
the cannabis users reported childhood problems with parents, school, friends or police 
(22 per cent versus 16 per cent stated at least on of these). Problems with parents were 
reported most frequently in both samples (13 and 9 per cent, respectively) whereas 
problems with the police were stated by 3 per cent of the cannabis users and 2 per cent 
of the whole sample. 
As expected, the cannabis users reported a higher lifetime prevalence of alcohol 
and illicit drugs. Practically every cannabis user had used alcohol (99 per cent) 
compared to 92 per cent in the full sample, and the corresponding numbers for 
amphetamine and cocaine use were 30 versus 13 per cent and 26 versus 11 per cent, 
respectively. The heroin prevalence was relatively low in both groups (3 and 1 per cent, 
respectively. For all drugs, substantially smaller fractions reported frequent use, defined 
as use on 25 or more occasions. The debut ages did not differ between the groups, and 
in line with the pattern for initiation found in other studies, the average debut ages 
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suggest that drug consumers in Oslo start to use alcohol prior to cannabis, then proceed 
to amphetamine, heroin and cocaine. 
There are also significant overlaps between the use of different drugs. The low 
prevalence of heroin implies that many in the sample have used only amphetamine or 
cocaine without also using heroine. However, almost all heroin users had also used 
other drugs (amphetamine and or cocaine), and 61% of those who had tried either 
amphetamine or cocaine had also used the other drug.
There is no way of knowing which came first for individuals who report that 
they have used both cannabis and hard drugs in the same year (6% of the final sample). 
In order not to make the unsupported assumption that cannabis came first, our 
specification makes the probability of using hard drugs depend on cannabis 
consumption in the previous years, not the current year.
Figure 1 illustrates the “staircase” in drug use initiation where the highest hazard 
rate for starting with alcohol peaks at an earlier age than the highest hazard rate for 
cannabis use and use of amphetamine and cocaine. The hazard rate figure for heroin is 
left out due to the small sample size (n=24) and compared to the other substances it 
indicates a less uniform pattern. The hazard rates give the probabilities for various age 
groups of starting with a drug given that the person has not started up to that age.
(Figure 1 about here)
The “staircase” pattern is also confirmed when we examine the individual ages 
of initiation for the various drugs. 92% of heavy drug users claimed to have used 
cannabis before any of the hard drugs. Less than 5 per cent reported a lower debut age 
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for amphetamine than for cannabis, 1 per cent a lower debut age for cocaine and no one 
claimed to have started with heroin before they tried cannabis for the first time. Further, 
nearly all hard drug users seem to have used cannabis at some point and only 4 of the 
254 amphetamine users, 5 of the 218 cocaine users and 1 of the 24 heroin users claimed 
no cannabis experience.  
It is well known that in general surveys like the one used here, homeless and 
institutionalized people are under-represented, as are people with various sorts of 
deviant behavior. However, the relatively high reported prevalence of illicit drug use in 
the present sample indicates that many drug users do respond to postal questionnaires. 
Still, to validate our data we have compared prevalence rates for life-time drug use to 
two recent Norwegian studies employing alternative sampling procedures but covering 
the same age groups. The Norwegian Institute for Alcohol and Drug Research conducts
on a regular basis national surveys in which interviewers visit households drawn from a 
central register (see Horverak (2006) for more details about the procedure). Alcohol 
related questions are asked face-to-face whereas a self-filled questionnaire is used for 
information about illicit drug use. In addition a longitudinal dataset based on a 
representative sample of youngsters recruited in a 1992 school survey (mean age 15) 
and followed to 2005 (mean age 28) collected drug use information (Pedersen, 2008). 
Despite different survey designs, these datasets yield comparable prevalence figures to 
the present. All three samples, however, are likely to be more representative for 
recreational than hard core drug users.
Recall bias may be a problem, as people are asked to recall the debut age of 
behaviors in the past. One may argue, however, that using an illicit drug for the first 
time is a unique event and that users will tend to remember it. In line with this, one 
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recent study of response reliability in adolescent substance use progression suggests that 
the initiation sequences were reported consistently when checked again three years after 
the first interview (Golub et al. 2000).
3.2 The price data
In order to examine the economic aspects of drug use more than 3,500 interviews with 
drug injectors visiting the needle exchange service in Oslo have been conducted since 
1993.   Interview sessions were first held on a monthly basis, then quarterly from June 
1994 and bi-annual since September 1997. The interviews were anonymous. In addition 
to some background variables, interviewees were asked detailed questions about their 
level and source of monthly income, levels of drug consumption and the prices they had 
paid for the different types and quantities of drugs. Given both the number of interviews 
and the fact that this was the only major needle-exchange service in Oslo during this 
period, the data is considered to accurately reflect the overall price level of drugs in 
Oslo. More details about the sampling procedure and representativeness can be found in 
Bretteville-Jensen and Biørn (2003).
We use annual median prices for the different drugs and the nominal prices are 
deflated by the consumer price index (CPI 1998=100). The prices are reported for small 
quantity sales: we use the price of 1 gram of cannabis, ¼ gram of amphetamine and 
cocaine and 1/24 gram of heroin. The survey does not provide price data for the period 
1988-1992. Such data are needed for a minority of the sample since some of the 
youngsters in the sample set turned 12 during those years (The starting age for inclusion 
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in the pseudo-panel data set). According to information from the drug section of the 
Oslo police nominal drug prices were very stable during the first period, so we have 
used deflated 1993-prices for those years. For cocaine, police records of prices are used 
throughout the period.
With the exception of cocaine, inflation adjusted drug prices were substantially 
reduced the last half of the study period (Figure 2). Heroin in particular, has become 
cheaper. In 1988 users were charged more than 400 Norwegian kroner (NOK) for the 
smallest unit sold at the market whereas the equivalent price in 2002 was less than 100 
NOK. The price of amphetamine has also fallen substantially whereas cocaine users 
paid around the same in 2002 as in 1988. Nominally, the price of one gram of cannabis 
has been stable throughout the period although the CPI deflated price has fallen. 
(Figure 2 about here)
4 Results
We first present the results from the univariate and the bivariate hazard models, then a 
more detailed examination of the gateway variable. Thereafter, we examine more 
closely the two groups that the model identifies and test the robustness of the model. As 
our main interest is the possible gateway effect of cannabis, only the results for the 
hazards of hard drug use are presented (the full set of results are available upon request).
Our preferred specification uses the logistic hazard model and relies on exclusion 
restrictions (the price variables) as well as on the timing of events to identify the 
gateway effect. 
20
The univariate hazard model for initiation of hard drugs provides a benchmark 
for the subsequent analyses. The results from running a separate logistic hazard 
equation, that does not take unobserved heterogeneity into account, suggest that 
cannabis is a statistically significant stepping stone to the use of harder drugs (see Table 
2). The dummy variable for cannabis initiation in the past four years is statistically
significant at the 1-percent level. Childhood problems and the price of heroin also seem 
to have a significant impact on the uptake of hard drug use and the hazard increases 
with time (age).
(Table 2 about here)
The results from the bivariate hazard model with shared frailty reveal that the 
picture changes when unobserved heterogeneity is taken into account. In the latent class 
model each individual is assumed to belong to one out of two groups. For those 
belonging to Group 1, the coefficient for recent cannabis use is statistically significant 
only at a 10 per cent level. In contrast, cannabis is a statistically significant predictor of 
later hard drug use for those who belong to Group 2. Among the other explanatory 
variables, Table 2 shows that the coefficients for childhood problems, heroin price and 
time are statistically significant for Group 1 whereas gender, childhood problems, 
amphetamine and cocaine prices and time are statistically significant for Group 2.
(Figure 3 about here)
Group membership is unknown but posterior probabilities of class membership 
can be computed using Bayes rule. A histogram of these posterior probabilities reveals 
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that most of the individuals share a high probability of having a latent characteristic that 
makes them belong together in one group (labeled “Group 1”, see Figure 3) To learn 
more about the groups, we split the sample so that those with an estimated probability 
of 0.5 or more for belonging to Group 1 are assigned to that group (n=617) whereas the 
remaining individuals are put in Group 2 (n=194). The descriptive statistics of 
individuals in Group 1 show no extreme values on any of the background variables (see 
Table 3). The second group is interesting in the sense that it consists of a subset of what 
one might call “troubled youths.” They do worse on the background variables 
(childhood problems with police, school, friends and parents) as well as reporting to 
have started their illicit drug use at an earlier age (e.g. mean debut age for cannabis is 
15.6 versus 18.9 in Group 1). Group 2 not only states a much higher life time 
prevalence of amphetamine, cocaine and heroin use but also a more frequent use of 
illicit drugs. More than 80 per cent among the “troubled youths” reported that they had 
used cannabis on more than 25 occasions and 57 per cent had as frequent use of 
amphetamine. The corresponding numbers for the larger group of sample are 35 and 29 
per cent, respectively.     
(Table 3 about here)
Figure 4 and Table 4 provides more details about the hazard rates and the
magnitude of the estimated gateway effect for the two groups. Figure 4 compares the 
average estimated hazard for the use of heavy drugs in Group 1 and Group 2 at different 
ages. Both curves peak at around the age of 20, but the estimated hazard is much larger 
for Group 2 than Group 1. This difference underlines the argument that it is important to 
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distinguish between groups when discussing the gateway effect since the magnitude of 
the effects seems to differ greatly depending on which latent class someone belongs to. 
(Figure 4 about here)
In Table 4 the first row presents estimates of the hazard rate for the ‘untreated’
( 0h ) evaluated with recent initiation of cannabis (the gateway effect) set to zero and at 
the means of the other regressors. This gives a sense of the rate of initiation of hard drug 
use in the absence of a gateway effect. As expected the estimated probability of 
initiating use of hard drug without recent cannabis use is low and close to zero for 
Group 1. All estimates for the hazard rate increase when evaluated with recent use of
cannabis set to one, as shown in the second row. The third row presents estimates of the 
partial effect ( 01h h ): the difference in hazard rates with and without recent use of 
cannabis evaluated as the mean of the regressors. This shows how the hazard of hard 
drug initiation is increased by the gateway effect. In absolute terms recent cannabis use 
is estimated to have a relatively small impact on the initiation of hard drugs for Group 1 
(0.00023) and a larger one for Group 2 (0.025). As the last row shows, the odds ratios 
for the gateway effect ( 01 /h h ) are substantial. For Group 2 this is statistically 
significant and recent use of cannabis almost doubles the hazard of later hard drug use. 
One should, however, be careful not to equate a statistically significant gateway 
coefficient with a strong gateway effect. Moreover, the results do not imply that 
cannabis users in this sample are twice as likely to become frequent hard drug 
users/addicts since only a small minority of those who try hard drugs report to have 
used any hard drug 25 times or more. 
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(Table 4 about here)
An interpretation of the main findings is that for most people, the influence of 
recent cannabis use is relatively low and only statistically significant at a 10 per cent 
level. Still, from this level, the risk of taking up drugs like cocaine, amphetamine or 
heroin increases by one third after initiating cannabis. On the other hand, the sample 
consists of a minority of individuals whose hazards for hard drugs do increase 
significantly after having used cannabis. The unobserved characteristic – genetic 
composition, time preferences or upbringing - seem to make the individuals in this 
group more vulnerable to the influence cannabis may have on later hard drug use.
5 Checks for robustness
Computation of latent class models is prone to problems due to local optima. To 
examine the robustness of the results, the analysis was repeated with different starting 
values (for individual group membership) and the process of convergence was traced.  
The algorithm produced a likelihood that increased gradually and monotonically 
towards a maximum. Repeated tests using different starting points also showed that the 
routine converged to the same solution regardless of the starting point, indicating that 
the maximum really is a global maximum.
In an effort to further assess the sensitivity of the results to the specification of 
the model and the data, we used the same latent class model but with changes in the 
model specification. The aim was to examine the stability of the results. Clearly one 
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would not expect precisely the same estimates, but if the general pattern is robust one 
would be more inclined to accept the conclusions and less fearful that the estimates 
were driven by specification issues in the modelling.
First, the model also gave robust results when we shortened the incubation 
period: the length of time in which cannabis could be viewed as causally important 
(Table 5). Decreasing the original 4-year time window to 2 years and re-running the 
analysis produced comparable results: two distinct groups, one small group with a 
statistically significant gateway coefficient and another group in which the effect was 
smaller and/or statistically insignificant (at the 5-percent level).
Second, models with no exclusion restrictions were tested – both by including 
and excluding the price of all the drugs in all the equations. Both specifications gave 
similar general results: a small group for whom cannabis was an important gateway 
drug and a larger group in which it was weak or statistically not significant. This result 
is worth emphasizing since previous studies have not had access to the similar data on 
prices.  Given that the price of heroin fell during the period of our analysis, one would 
expect an increase in the uptake of hard drugs. A model which did not include prices 
might attribute this general trend to a larger gateway effect. Excluding prices could then 
lead to an overestimation of the effect. In line with this we find that the coefficient on 
the gateway dummy is larger when we exclude price information, but at the same time 
we also show that including prices does not eliminate the gateway effect for the 
“troubled youths.” In this way the results seem to support the overall conclusion that 
this is a vulnerable group.
Third, an alternative specification with different variables was tested. In this 
model cocaine price was left out both because its relevance was low (cocaine 
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prevalence in Norway was not very high at that point in time) and the data on cocaine 
prices was from a different source than the other price data (police records instead of 
our own interviews). Also the problem variable was split so “problems with the police” 
became a separate variable as opposed to being a part of the aggregate index that was 
originally used as a “problem variable.” This model also gave results that were in line 
with the benchmark model which further strengthens the belief that the general result is 
not driven by minor issues in the specification.
In the empirical analysis presented it is assumed that the unobserved 
heterogeneity divides the sample into two groups. To test whether this is a reasonable 
assumption, a model with three groups was also estimated. However, in this model the 
solutions became unstable as the algorithm gave different answers for different starting 
values. This reflects the problems of local optima, identification and convergence for 
over-parameterized models. For more on accuracy and problems of estimating these 
kinds of models see Gaure et al. (2007). 
Finally, in order to reduce unobserved heterogeneity the benchmark model was 
originally estimated using only those respondents who had tried cannabis (41% of the 
full sample). To test the importance of this restriction, we estimated a model using the 
full sample. Once again the algorithm separated the sample into one large and one 
smaller group (34% of the sample). The marginal effect of recent cannabis use on the 
probability of using hard drugs was statistically significant in the small group at the 
10% level, but not in the large group. Also the marginal effect was almost three times 
larger in the small group than the larger group (0.0037 vs. 0.0013). This indicates that 
the general direction of the results are robust both to changes in the specification and to 
changes in the sample. 
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(Table 5 about here)
6 Conclusions
The commonly observed sequential pattern of drug use initiation may well be explained 
by an increased risk of starting to consume a more harmful drug after first having used a 
soft drug but there could also be other factors influencing the uptake of various drugs. 
As no survey, no matter how detailed, will include all potentially important variables, 
testing the influential gateway hypothesis imposes a statistical challenge. This paper has 
argued that the issue of unobserved individual heterogeneity is central, that the 
empirical methods should take into account time-varying covariates like prices and that 
it should make as few restrictions on the model as possible. After developing such a 
model, based on a bivariate discrete time hazard model with shared frailty, the 
conclusion from the empirical findings is that the gateway effect of cannabis is 
statistically significant for a sub-group of “troubled youths.” Within this group the risk 
of taking up hard drugs doubles after the initiation of cannabis. For most youths, 
however, the gateway coefficient was only statistical significant at a 10% level, and the 
marginal effect was relatively small. Still, the results indicate that the hazard for hard 
drug initiation would increase by one third during a four year “incubation period” 
following cannabis initiation.
The results underline the importance of adopting a general approach in which all 
the coefficients are allowed to vary. The large differences between some of the 
coefficients in the two groups indicate this and statistical tests of the hypothesis that the 
coefficients in the two latent classes are similar are clearly rejected. This may explain 
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some of the discrepancy between our results and Pudney (2003) and van Ours (2003). 
Pudney, and to some extent van Ours, argue that the gateway effect is greatly reduced 
after taking unobserved heterogeneity into account. A more general test in which all 
variables are allowed to vary reaches a more nuanced conclusion in which the gateway 
effect actually increases for almost a quarter of the sample when comparing their results 
to that of the full sample. 
The finding of a statistical significant gateway effect is, however, in line with 
recent studies using alternative approaches for taking account of unobserved 
heterogeneity. DeSimone (1998), employing an IV technique, finds that previous 
cannabis use increases the probability of subsequent cocaine use by 29 percentage 
points. As mentioned in Section 2, finding valid instruments are challenging. Fergusson 
et al. (2006) examined the association between frequency of cannbis use and the use of 
other illicit drugs. They report a strong association between cannabis use and 
subsequent hard drug use and it was particularly strong during adolescence. Their 
chosen fixed effect approach, which requires panel data with sufficient within-variation 
in the dependent variable and regressors, cannot be used however, to model “one-off” 
decisions such as whether or not to try a harder drug. Bretteville-Jensen et al. (2008) 
examine the influence of previous drug use on subsequent regular use (>25 times) of 
cannabis, amphetamine and cocaine. Although substantially reduced after unobserved 
factors are taken into account they find a statistically significant gateway effect for all 
three drugs tested. Unfortunately, the multivariate probit approach cannot take time-
varying covariates, like drug prices, into account. The present study adds to this 
gateway literature by introducing a flexible approach which, among other things, allows 
for testing separate gateway effects for subgroups of cannabis users.
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As previously described, there are at least four possible mechanisms 
underpinning an observed gateway effect. A better understanding of these mechanisms 
is needed but beyond the scope of this paper. It is important to notice, however, that the 
finding of a gateway effect need not necessarily undermine moves to liberalize cannabis 
laws. If the driving force behind cannabis users’ initiation of hard drugs is that they 
come in contact with hard drug users whom they not otherwise would have met, a 
separation of the markets for soft and hard drug, for instance in line with the Dutch 
model, could be an option. Further, if people, after experiencing no obvious ill effects of 
soft drug use, have reduced confidence also in the strong negative publicity directed 
against hard drug use, the solution may be to make the differences between the various 
drugs more distinct in information material and campaigns directed against illicit drug 
use. If, on the other hand, it is the addiction or the adjustment cost effects that operate, a 
liberalization of penal sanctions may be undesirable, even though the number of 
additional hard drug users resulting from the policy change may be quite modest. 
Whatever mechanism or combinations of mechanisms that operates it seems 
clear that one group of cannabis users are more vulnerable to the effect cannabis use has 
on subsequent hard drug use. We saw that not only did they start to consume illicit 
drugs at a younger age, a substantially larger proportion also used drugs like 
amphetamine and heroin more intensively, i.e. more people in this group reported to 
have used these drugs on more than 25 occasions. They also reported more childhood 
problems with police, parents, friends and school. Whether the underlying reasons are 
childhood traumas, negative peer influence, high time preferences, less beneficial 
genetic endowments or other factors, the “troubled youths” seem to have less resistance 
with respect to further drug involvement. Thus, some policy implications of the findings 
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may still be suggested: Early identification of the “troubled youths” and adequate help 
to minimize the effect of their risk factors can be effective in reducing the number of 
hard drug users. 
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Table 1  Variable definitions and descriptive statistics (Full sample, n=1,984; Cannabis 
users only, n= 811 )
Variable 
Label
Variable Definition Full sample Cannabis users
Mean Std.dev. Mean Std.dev.
Age Age in years 24.1 1.64 24.0 1.66
Gender Dummy; 1 if male 0.38 0.49 0.44 0.50
Parents Dummy; 1 if problems with parents 0.09 0.29 0.13 0.34
School Dummy; 1 if problems at school 0.07 0.26 0.10 0.30
Friends Dummy; 1 if problems with friends 0.04 0.20 0.05 0.21
Police Dummy; 1 if problems with police 0.02 0.13 0.03 0.16
Childhood 
Problems
Dummy; 1 if any problems 0.16 0.37 0.22 0.41
Alcohol Dummy; 1 if ever used alcohol 0.92 0.27 0.99 0.09
Cannabis Dummy; 1 if ever used cannabis 0.41 0.49 1 1
Amphetamine Dummy; 1 if ever used amphetamine 0.13 0.33 0.30 0.46
Cocaine Dummy; 1 if ever used cocaine 0.11 0.31 0.26 0.44
Heroin Dummy; 1 if ever used heroin 0.01 0.11 0.03 0.16
Hard drugs Dummy; 1 if ever used hard drugs 0.16 0.36 0.36 0.48
Alco-age Debut age for first use of alcohol 15.3 2.25 14.5 1.96
Cann-age Debut age for first use of cannabis 18.0 2.76 18.1 2.73
Amph-age Debut age for first use of amphetamine 18.8 2.39 18.8 2.30
Hero-age Debut age for first use of heroin 19.5 2.57 19.6 2.67
Coca-age Debut age for first use of cocaine 20.0 2.32 19.9 2.32
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Table 2    Coefficient estimates for hazard models for hard drug use 
Single equation model Latent class models 
(taking unobserved heterogeneity into account)





























































* Significant at 10-percent level
** Significant at 5-percent level
*** Significant at 1-percent level
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Table 3  Differences between the clusters in the latent class analysis
Group 1, n = 617 
(Most youths),
Group 2, n = 194
(“Troubled youths”),
Variable Mean St. dev. Mean St. dev
Gender (percentage male) 44.2 0.497 42.3 0.495
Percentage with reported use of …
     … amphetamine (0/1) 13.0 0.336 85.1 0.357
     … heroin (0/1) 0.6 0.080 8.8 0.283
     … cocaine (0/1) 11.0 0.313 72.7 0.447
Mean age of starting to use …
     …cannabis 18.9 2.518 15.6 1.485
     …amphetamine 20.6 1.887 18.1 2.044
     …heroin 21.0 1.547 19.3 2.845
Frequency of use (percentage reported to 
have used the drug more than 25 times) …
     …cannabis 35.2    0.478 82.5 0.381
     …amphetamine 28.8 0.455 57.0 0.497
     …heroin 0 0 41.2 0.507
Percentage with serious childhood 
problems 
     … with the police 1.3 0.113 7.2 0.259
     … in school 8.9 0.285 13.9 0.347
     … with friends 4.5 0.208 5.2 0.222
     … with parents 13.0 0.336 14.9 0.357
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Latent class models 
Taking unobserved heterogeneity into account
Group 1 Group 2 
























* Significant at 10-percent level
** Significant at 5-percent level
*** Significant at 1-percent level
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Benchmark model 0.710*** 194 0.295* 617
Short incubation period (2 years) 0.684*** 162 0.351* 649
Including all price variables in all 
equations
0.53*** 178 0.43 633
Including no price variables 0.93*** 234 0.000 577
Using only amphetamine as hard drug 1.3*** 216 -1.0*** 595
Using only cocaine as hard drug 0.53*** 223 26.4 588
New specification (see text) 0.93*** 230 0.28 645
* Significant at 10-percent level
*** Significant at 1-percent level
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Kaplan-Meier Hazard Functions; 
Cannabis, Amphetamine and Cocaine
Cannabis Amhetamine Cocaine
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cannabis amphetamine cocaine heroin
*Note: The prices relates to the following quantities of the drugs: 1 gram of cannabis, ¼ gram of 
amphetamine, ¼ gram of cocaine and 1/24 gram of heroin. The prices have been deflated by the 
CPI (1998=100).
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